文献速递银屑病与炎症性皮肤病

Crisaborole 2%软膏治疗间擦、肛门生殖器及面部银屑病:双盲随机赋形剂对照试验

Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2019-07-03

该双盲随机赋形剂对照试验纳入21例间擦、肛门生殖器及面部银屑病患者,按2:1随机接受crisaborole 2%软膏(n=14)或赋形剂(n=7)每日两次治疗4周,随后开放标签crisaborole治疗4周。4周时crisaborole组皮损改善66%,赋形剂组为9%(P=.0011);开放标签阶段至第8周改善达81%,其中71%达临床清除,未报告不良事件。

要点

  • crisaborole 2%软膏每日两次治疗4周,间擦、肛门生殖器及面部银屑病皮损改善66%,优于赋形剂的9%(P=.0011)
  • 继续开放标签治疗至第8周,皮损改善达81%,71%患者达临床清除
  • 研究中未报告不良事件,提示局部耐受性良好

核心结论

  • crisaborole 2%软膏治疗间擦、肛门生殖器或面部银屑病耐受性良好,并带来临床改善。

研究设计与样本

  • 双盲、随机、赋形剂对照试验,共纳入21例参与者。
  • 参与者按2:1随机接受crisaborole 2%软膏(n=14)或赋形剂软膏(n=7)每日两次治疗4周,随后接受4周开放标签crisaborole 2%软膏治疗。
  • 疾病严重程度采用目标皮损严重程度量表(TLSS)评估。

主要发现

  • 治疗4周后,crisaborole组皮损改善66%,赋形剂组改善9%(P=.0011)。
  • crisaborole组在开放标签阶段持续改善,至第8周皮损改善达81%。
  • 至第8周,71%的crisaborole组参与者达到临床清除。
  • 研究中未报告不良事件。

关键数值与推荐

  • 4周时皮损改善:crisaborole组66%,赋形剂组9%(P=.0011)。
  • 第8周时皮损改善81%,71%参与者达临床清除。

临床怎么用

  • 对于间擦、肛门生殖器及面部银屑病,可考虑使用crisaborole 2%软膏每日两次作为局部治疗选择。
  • 治疗4周可见改善,延长至8周可能进一步提高改善率并实现临床清除。

局限性

  • 研究局限于单一三级医疗中心。
  • 样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis of the intertriginous, anogenital, and facial regions remains a therapeutic challenge, with current algorithms lacking a topical agent that exhibits both high efficacy and minimal side effects. OBJECTIVE: To assess the safety and efficacy of crisaborole 2% ointment-a nonsteroidal phosphodiesterase 4 inhibitor-in the treatment of intertriginous, anogenital, and facial psoriasis. METHODS: A double-blind, randomized, vehicle-controlled trial was conducted in 21 participants. Participants were randomized 2:1 to receive 4 weeks of twice-daily treatment with either crisaborole 2% ointment (n = 14) or vehicle ointment (n = 7), followed by 4 weeks of open-label treatment with crisaborole 2% ointment. Disease severity was measured by using the Target Lesion Severity Scale (TLSS). RESULTS: After 4 weeks, participants in the crisaborole group demonstrated 66% improvement compared with 9% in the vehicle group (P = .0011). Participants in the crisaborole group continued to experience improvement through the open-label phase, demonstrating 81% lesional improvement by week 8, with 71% of these participants achieving clinical clearance. There were no adverse events. LIMITATIONS: The study was limited to a single tertiary care center and small sample size. CONCLUSION: Treatment with crisaborole 2% ointment was well-tolerated and led to clinical improvement in participants with intertriginous, anogenital, or facial psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Hashim PW, Chima M, Kim HJ, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol. 2019. PMID: 31279028. doi:10.1016/j.jaad.2019.06.1288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。